Pharmacokinetics and dopamine/acetylcholine releasing effects of ginsenoside Re in hippocampus and mPFC of freely moving rats

Acta Pharmacologica Sinica

Volumn 34, Issue 2, 2013, Pages 214-220

  Shi, Jing ^a,b   Xue, Wei ^b   Zhao, Wen Jie ^c   Li, Ke Xin ^b  

^a BEIJING HUILONGGUAN HOSPITAL   (China)

^b BEIJING HOSPITAL   (China)

^c Beijing SL Pharmaceutical Co Ltd   (China)

Author keywords

acetylcholine; cerebrospinal fluid; dopamine; ginsenoside Re; hippocampus; learning and memory; medial prefrontal cortex (mPFC); microdialysis; pharmacokinetics

Indexed keywords

ACETYLCHOLINE; DOPAMINE; GINSENOSIDE RE;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID; DOPAMINE RELEASE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG HALF LIFE; HIPPOCAMPUS; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; NONHUMAN; PHARMACOKINETICS; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; VENTROMEDIAL PREFRONTAL CORTEX;

ACETYLCHOLINE; ANIMALS; DOPAMINE; DOPAMINE AGENTS; GINSENOSIDES; HIPPOCAMPUS; MALE; MICRODIALYSIS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84873549615     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.147     Document Type: Article

References (37)

1. Lanari A, Amenta F, Silvestrelli G, Tomassoni D, Parnetti L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech Ageing Dev 2006; 127: 158-65.
2. Chen KH, Reese EA, Kim HW, Rapoport SI, Rao JS. Disturbed neurotransmitter transporter expression in Alzheimer's disease brain. J Alzheimers Dis 2011; 26: 755-66.
3. Winkler J, Suhr ST, Gage FH, Thal LJ, Fisher LJ. Essential role of neocortical acetylcholine in spatial memory. Nature 1995; 375: 484-7.
4. Wallace TL, Porter RH. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol 2011; 82: 891-903.
5. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
6. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122-6.
7. Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG. Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav 2011; 99: 130-45.
8. Sugimoto H. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis. Chem Biol Interact 2008; 175: 204-8.
9. Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011; 155: 219-29.
10. Aalto S, Bruck A, Laine M, Nagren K, Rinne JO. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci 2005; 25: 2471-7.
11. Rinne JO, Sako E, Paljarvi L, Molsa PK, Rinne UK. Brain dopamine D-2 receptors in senile dementia. J Neural Transm 1986; 65: 51-62.
12. Shu SY, Bao X, Li S, Niu D, Xu Z, Li Y. A new subdivision of mammalian neostriatum with functional implications to learning and memory. J Neurosci Res 1999; 58: 242-53.
13. Jurgensen S, Antonio LL, Mussi GE, Brito-Moreira J, Bomfim TR, De Felice FG, et al. Activation of D1/D5 dopamine receptors protects neurons from synapse dysfunction induced by amyloid-beta oligomers. J Biol Chem 2011; 286: 3270-6.
14. Kemppainen N, Laine M, Laakso MP, Kaasinen V, Nagren K, Vahlberg T, et al. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci 2003; 18: 149-54.
15. Raybon JJ, Boje KM. Pharmacokinetics and pharmacodynamics of gamma-hydroxybutyric acid during tolerance in rats: effects on extracellular dopamine. J Pharmacol Exp Ther 2007; 320: 1252-60.
16. Kielbasa W, Kalvass JC, Stratford R. Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. Drug Metab Dispos 2009; 37: 137-42.
17. Zhu W, Hu H. A survey of TCM treatment for Alzheimer's disease. J Tradit Chin Med 2007; 27: 226-32.
18. Wu TY, Chen CP, Jinn TR. Traditional Chinese medicines and Alzheimer's disease. Taiwan J Obstet Gynecol 2011; 50: 131-5.
19. Howes MJ, Houghton PJ. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav 2003; 75: 513-27.
20. Helms S. Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 2004; 9: 259-74.
21. Zhao Y, Liu JP, Lu D, Zhao Y, Li PY. Improvement effect of ginsenoside Re on learning and memory abilities of natural apolexis eats and its mechanisms. Tradit Chin Drug Res Clin Pharm 2007; 18: 20-2.
22. Jiang HL, Yang Z, Meng Q, Hong T. Improvement and mechanism of ginsenoside Re on learning and memory deficts of mice. Chin Pharm Bull 2008; 24: 1399-40.
23. Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 2005; 30: 1986-95.
24. Liu L, Huang J, Hu X, Li K, Sun C. Simultaneous determination of ginsenoside (G-Re, G-Rg1, G-Rg2, G-F1, G-Rh1) and protopanaxatriol in human plasma and urine by LC-MS/MS and its application in a pharmacokinetics study of G-Re in volunteers. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 2011-7.
25. Wang A, Wang CZ, Wu JA, Osinski J, Yuan CS. Determination of major ginsenosides in Panax quinquefolius (American ginseng) using highperformance liquid chromatography. Phytochem Anal 2005; 16: 272-7.
26. Peng D, Wang H, Qu C, Xie L, Wicks SM, Xie J. Ginsenoside Re: Its chemistry, metabolism and pharmacokinetics. Chin Med 2012; 7: 2.
27. Liu YW, Zhu X, Li W, Lu Q, Wang JY, Wei YQ, et al. Ginsenoside Re attenuates diabetes-associated cognitive deficits in rats. Pharmacol Biochem Behav 2012; 101: 93-8.
28. Jing FC, Chen H, Li CL. Rapid determination of dopamine and its metabolites during in vivo cerebral microdialysis by routine high performance liquid chromatography with electrochemical detection. Biomed Environ Sci 2007; 20: 317-20.
29. Carlsson A, Sharp T, Zetterstrom T, Ungerstedt U. Determination of dopamine and its metabolites in small volumes of rat brain dialysates using small-bore liquid chromatography with electrochemical detection. J Chromatogr 1986; 368: 299-308.
30. Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 2002; 956: 349-57.
31. DeBoer P, Abercrombie ED. Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes. J Pharmacol Exp Ther 1996; 277: 775-83.
32. Joo KM, Lee JH, Jeon HY, Park CW, Hong DK, Jeong HJ, et al. Pharmacokinetic study of ginsenoside Re with pure ginsenoside Re and ginseng berry extracts in mouse using ultra performance liquid chromatography/mass spectrometric method. J Pharm Biomed Anal 2010; 51: 278-83.
33. Stormer VS, Passow S, Biesenack J, Li SC. Dopaminergic and cholinergic modulations of visual-spatial attention and working memory: Insights from molecular genetic research and implications for adult cognitive development. Dev Psychol 2012; 48: 875-89.
34. Vitiello B, Martin A, Hill J, Mack C, Molchan S, Martinez R, et al. Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropsychopharmacology 1997; 16: 15-24.
35. Levin ED, McGurk SR, Rose JE, Butcher LL. Cholinergic-dopaminergic interactions in cognitive performance. Behav Neural Biol 1990; 54: 271-99.
36. Li X, Wang G, Sun J, Hao H, Xiong Y, Yan B, et al. Pharmacokinetic and absolute bioavailability study of total panax notoginsenoside, a typical multiple constituent traditional Chinese medicine (TCM) in rats. Biol Pharm Bull 2007; 30: 847-51.
37. Bae EA, Shin JE, Kim DH. Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect. Biol Pharm Bull 2005; 28: 1903-8.